IFN-EC-Lipint for internal use 250 thousand IU №5

IFN-EU-Lipint^® developed by Vektor-Medika specialists, taking into account the needs of doctors and patients in an easy-to-use, safe and effective Interferon for the treatment of viral diseases such as influenza, tick-borne encephalitis, hepatitis B, hepatitis C and many others in adults and children.
By itself, interferon is rapidly destroyed by the aggressive environment of the stomach or blood enzymes, therefore, conventional interferon preparations are made in the form of injections or suppositories. This limits their effectiveness and requires the use of high doses, which increases side effects.
IFN-EU-Lipint^® - A new, liposomal drug interferon. This means that the interferon molecules are placed inside the smallest bioparticles, which are called liposomes. Such a biocontainer protects interferon from destruction in the aggressive environment of the stomach, allows it to circulate longer in the blood and retain its activity longer.
Thanks to the liposome, interferon retains all its medicinal properties and very rarely causes side effects. Prolonged circulation of liposomal interferon in the blood provides the same therapeutic effect, but using a lower dose than interferon in suppositories or in the form of injections.
IFN-EU-Lipint^® Available in dosage vials for adults and children from 3 years. Convenient drinking form and neutral taste of the drug are especially appreciated in pediatrics. Patients with severe sore throat or developed vomiting reflex also prefer interferon in vials, IFN-EU-Lipint^®.

Composition

In one bottle contains: the active substance - 250 thousand IU, 500 thousand IU or 1 million IU of Interferon Alfa-2b human recombinant; excipients: sodium chloride - 8.01 mg, sodium hydrogen phosphate dodecahydrate - 4.52 mg, sodium dihydrophosphate dihydrate - 0.56 mg, Lipoid C100 (phospholipids [mixture with a percentage of phosphatidylcholine not less than 94%]) - 41.18 mg, cholesterol - 4.53 mg, alpha-tocopherol acetate - 0.56 mg, lactose monohydrate - 91.34 mg. Powder or porous mass of white or yellowish color. Peeling is allowed, in whole or in part, from the surface of the glass of the vial to form a tablet-like shape. Hygroscopic.
It has an immunomodulatory and antiviral effect.

Immunobiological and pharmacological properties

Human recombinant interferon alpha-2b, which is an active substance in the preparation, is synthesized by bacterial cells of Escherichia coli strain SG-20050 / pIF16, in the genetic apparatus of which the human interferon alpha-2b gene is inserted. It is a protein containing 165 amino acids, and is identical in characteristics and properties to human leukocyte interferon alpha-2b.
The antiviral effect of interferon alpha-2b manifests itself during the reproduction of the virus by actively incorporating cells into metabolic processes.Interferon alpha-2b, interacting with specific receptors on the cell surface, initiates a series of intracellular changes, including the synthesis of specific cytokines and enzymes (2-5-adenylate synthetase and protein kinase), which inhibits the formation of viral protein and viral ribonucleic acid in the cell.
The immunomodulatory effect of interferon alpha-2b is manifested in an increase in the phagocytic activity of macrophages, an increase in the specific cytotoxic effect of lymphocytes on target cells, a change in the quantitative and qualitative composition of secreted cytokines; changes in the functional activity of immunocompetent cells; changes in the production and secretion of intracellular proteins.

Recommendations for use

- Complex therapy of patients with acute hepatitis B, chronic hepatitis B in active and inactive replicative forms, as well as chronic hepatitis B complicated by glomerulonephritis.
- Treatment of patients with atopic diseases, allergic rhinoconjunctivitis, bronchial asthma during specific immunotherapy.
- Prevention and treatment of influenza and ARVI in adults and children.
- Complex therapy of urogenital chlamydial infection in adults.
- Combined therapy of febrile and meningeal forms of tick-borne encephalitis in adults.
- Emergency prophylaxis of tick-borne encephalitis in combination with tick-borne immunoglobulin.

Dosage and administration

It is administered orally.
Immediately before use, add 1-2 ml of distilled or cooled boiled water to the contents of the vial. With shaking for 1-5 minutes a homogeneous suspension should form.
In the prevention and treatment of influenza and ARVI, the drug is taken 30 minutes before a meal:
- for prophylaxis: for adults and children over 15 years old - 500 thousand IU once a day, 2 times a week for 1 month during an increase in incidence; children from 3 to 15 years old - 250 thousand IU once a day, 2 times a week for 1 month during the rise in incidence.
- in the treatment of influenza and ARVI: adults and children over 15 years old - 500 thousand IU daily, 2 times a day for 3 days; children from 3 to 15 years old - 250 thousand IU daily, 2 times a day for 3 days.
With the treatment of tick-borne encephalitis, the drug is taken 30 minutes before meals:
- with febrile form: 500 thousand IU, 2 times a day (in the morning and in the evening) for 7 days;
- with meningeal form: 500 thousand IU, 2 times a day (in the morning and in the evening) for 10 days;
With emergency prevention of tick-borne encephalitis, the drug is taken 30 minutes before meals of 500 thousand IU 2 times a day (morning and evening) for 5 days. Tick-borne immunoglobulin is administered intramuscularly once no later than the 4th day after the tick bite at a dose of 0.1 ml / kg.
In acute hepatitis B, the drug is taken 30 minutes before meals according to the following scheme:
- Adults and children of school age - 1 million IU, 2 times a day for 10 days;
- children of preschool age (from 3 to 7 years) - 500 thousand IU 1 time per day for 10 days or, after control biochemical blood tests, a longer time - until complete clinical recovery.
In chronic hepatitis B in active and inactive replicative forms, as well as in chronic hepatitis B associated with glomerulonephritis, the drug is taken 30 minutes before meals according to the following scheme:
- for adults and children of school age - 1 million IU twice a day for 10 days and then for 1 month - every other day, once a day (for the night);
- children of preschool age (from 3 to 7 years) - 500 thousand IU twice a day for 10 days and then - 500 thousand IU for 1 month every other day, once a day (for the night).
When conducting specific immunotherapy, the drug is taken in the morning, 30 minutes after eating, according to the following scheme:
- for allergic rhinoconjunctivitis in adults - 500 thousand IU daily for 10 days (course dose 5 million IU);
- with atopic asthma for adults - 500 thousand IU once a day for 10 days, and then 500 thousand IU every other day for 20 days. The total duration of treatment is 30 days.
When complex treatment of urogenital infections in adults, the drug is taken 30 minutes before meals of 500 thousand IU daily, 2 times a day for 10 days.

Side effects

When applying the drug Reaferon-EC-Lipint in clinical studies of adverse reactions to the drug was observed. Given that the active substance is recombinant interferon alpha-2b, with the use of the drug Reaferon-EC-Lipint, side effects are typical for this group of drugs: chills, fever, asthenic symptoms (apathy, fatigue, lethargy) headaches, myalgias, arthralgia.These side effects are partially controlled by Indomethacin / Paracetamol. Allergic reactions may develop.
On the part of the digestive system: nausea, dry mouth, dyspepsia, loss of appetite.
On the part of the nervous system: with prolonged use, irritability, anxiety, insomnia, apathy, and depression are possible.
On the part of the endocrine system: possible changes on the part of the thyroid gland.
On the part of laboratory parameters: with prolonged use possible leukopenia, lymphopenia, thrombocytopenia.
Overdose
No cases of overdose were observed. May increase dose-dependent side effects. Symptomatic treatment.

Contraindications

- Hypersensitivity to interferon or any other components of the drug;
- severe forms of allergic diseases;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
- pregnancy and breastfeeding period.
Carefully
Hepatic and / or renal failure, severe myelosuppression, thyroid disease.
Use during pregnancy and during breastfeeding
The drug is contraindicated for use during pregnancy and during breastfeeding.

Interaction with other drugs

Interferon alpha-2b is able to reduce the activity of cytochrome P450 isoenzymes and, therefore, interfere with the metabolism of cimetidine, phenytoin, Dipyridamole, theophylline, diazepam, propranolol, Warfarin, some cytostatics.May enhance the neurotoxic, myelotoxic or cardiotoxic effects of drugs administered previously or simultaneously with it. Co-administration with drugs that depress the central nervous system and immunosuppressive drugs (including oral and parenteral forms of glucocorticosteroids) should be avoided.
Alcohol intake during treatment is not recommended.

special instructions

For diseases of the thyroid gland, the drug should be administered under the supervision of an endocrinologist. When signs of thyroid dysfunction appear on the background of therapy, it is recommended to control the concentration of thyroid stimulating hormone (TSH).
Influence on ability to drive vehicles and mechanisms
During the period of use of the drug in patients experiencing fatigue, drowsiness or disorientation, it is necessary to refrain from engaging in potentially hazardous activities that require high concentration of attention and quickness of psychomotor reactions.

Storage conditions

Store in a dark place at a temperature not higher than 8 ° C.
Keep out of the reach of children.